Zeno Management Inc. has divulged GTPase KRAS (mutant) inhibitors (particularly, KRAS (G12C mutant)) reported to be useful for the treatment of cancer.
Zeno Management Inc. has identified antibody-drug conjugates comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) covalently bound to exatecan derivatives through a linker.
Zeno Management Inc. researchers have prepared and tested azole compounds described as transcriptional enhancer factor (TEAD) inhibitors potentially useful for the treatment of autoimmune diseases, inflammation and cancer.
Macrocyclic compounds acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors have been reported in a Zeno Management Inc. patent. They are reported to be potentially useful for the treatment of cancer.
